HD-OPM Archive
Topics › Supplements & vitamins

JAMA Cardiology trial: vitamin K2 (MK-7) for 2 years slowed coronary calcium progression

Gokhan Can · Jun 10, 2026 · ♥ 37 reactions · 35 comments · original Facebook post
Supplements & vitaminsPlaque, CAC & CT angiography
AI summary & key facts

Admin says there is now solid evidence K2 slows coronary artery calcification, especially in people with existing calcification. In the new JAMA Cardiology RCT, MK-7 for two years reduced CAC progression versus placebo in symptomatic CAD, mainly by limiting new calcification in noncalcified plaques; effect on events is still unknown, and K2 is not recommended with warfarin.

There's now solid evidence that Vitamin K2 slows down coronary artery calcification in various patient groups, most notably in those with existing calcification.

Previous post summarized earlier trials and results: ↪ Vitamin K2 slows coronary calcium mainly in severe calcification; event benefit unproven

JAMA Cardilogy just published another positive trial today!

We still don't know how/if this affects cardiovascular events. (Supplementing with K2 is not recommended if you're on Warfarin -- always check with your Dr).

Research cited

In a randomized clinical trial, supplementation with #Menaquinone7 (MK-7) for 2 years produced a statistically significant reduction in the progression of #CoronaryArteryCalcification (CAC) compared to placebo in patients with symptomatic coronary artery disease.

The difference was most evident in the development of new calcifications within noncalcified plaques, although MK-7 had no impact on stenosis severity or total plaque volume. The trial found no relevant adverse effects, but the clinical significance for cardiovascular events remains to be determined.

Paper · JAMA Cardiol · 2026Two Years of Menaquinone-7 Supplementation and Coronary Artery CalcificationImportance Vitamin K supplementation can reduce progression of vascular calcification in patients with diabetes or end-stage kidney disease. Presently, it is unknown whether vitamin K is also beneficial in patients with symptomatic atherosclerotic coronary artery disease (CAD). Objective To evaluate whether supplementation with the vitamin K homologue menaquinone-7 (MK-7) for a period of 2 years attenuates the…jamanetwork.comNo photo description available.
← newer: Mergen and Hasselbalch review heart drugs, supplements and lolder: Retatrutide and other new GLP-1 drugs flagged as worth watch →